McKesson Beheer

Beheer criteriumcontroles 3/4

De CEO McKesson is Brian Tyler, benoemd in Apr2019, heeft een ambtstermijn van 5.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 19.00M, bestaande uit 7.8% salaris en 92.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.062% van de aandelen van het bedrijf, ter waarde R$ 292.95M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 3.2 jaar.

Belangrijke informatie

Brian Tyler

Algemeen directeur

US$19.0m

Totale compensatie

Percentage CEO-salaris	7.8%
Dienstverband CEO	5.6yrs
Eigendom CEO	0.06%
Management gemiddelde ambtstermijn	3.5yrs
Gemiddelde ambtstermijn bestuur	3.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Brian Tyler's beloning veranderd ten opzichte van McKesson's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$3b
Jun 30 2024	n/a	n/a	US$3b
Mar 31 2024	US$19m	US$1m	US$3b
Dec 31 2023	n/a	n/a	US$3b
Sep 30 2023	n/a	n/a	US$3b
Jun 30 2023	n/a	n/a	US$4b
Mar 31 2023	US$20m	US$1m	US$4b
Dec 31 2022	n/a	n/a	US$3b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	US$18m	US$1m	US$1b
Dec 31 2021	n/a	n/a	US$1b
Sep 30 2021	n/a	n/a	-US$5b
Jun 30 2021	n/a	n/a	-US$4b
Mar 31 2021	US$15m	US$1m	-US$5b
Dec 31 2020	n/a	n/a	-US$4b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$922m
Mar 31 2020	US$15m	US$1m	US$906m
Dec 31 2019	n/a	n/a	-US$905m
Sep 30 2019	n/a	n/a	-US$626m
Jun 30 2019	n/a	n/a	US$601m
Mar 31 2019	US$13m	US$929k	US$33m

Compensatie versus markt: De totale vergoeding ($USD 19.00M ) Brian } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de BR markt ($USD 5.72M ).

Compensatie versus inkomsten: De vergoeding van Brian is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Brian Tyler (57 yo)

5.6yrs

Tenure

US$18,997,543

Compensatie

Mr. Brian S. Tyler, Ph D., has been an Independent Director at Republic Services, Inc. since April 1, 2021. He served as Chairman of Supervisory Board at McKesson Europe AG since August 9, 2018 until 2022....

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Brian Tyler	CEO & Director	5.6yrs	US$19.00m	0.062% R$ 292.9m
Britt Vitalone	Executive VP & CFO	6.8yrs	US$6.78m	0.011% R$ 54.2m
Michele Lau	Executive VP & Chief Legal Officer	less than a year	US$8.81m	0.00011% R$ 519.1k
LeAnn Smith	Executive VP & Chief Human Resources Officer	1.9yrs	US$3.54m	0.0016% R$ 7.5m
Thomas Rodgers	Executive VP and Chief Strategy & Business Development Officer	4.4yrs	US$3.18m	0.0020% R$ 9.4m
Napoleon Rutledge	Senior VP	2.7yrs	geen gegevens	0.0015% R$ 7.3m
Francisco Fraga	Executive VP	1.1yrs	geen gegevens	geen gegevens
Rachel Rodriguez	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Pete Slone	Senior Vice President of Corporate Public Affairs	9.4yrs	geen gegevens	geen gegevens
Kirk Kaminsky	President of The US Pharmaceutical & Specialty Solutions Business	5.6yrs	geen gegevens	geen gegevens
Paul Smith	Senior Vice President of Taxes	no data	geen gegevens	geen gegevens
Kevin Emerson	Senior Vice President of Finance Operations	2.7yrs	geen gegevens	geen gegevens

3.5yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van M1CK34 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Brian Tyler	CEO & Director	5.6yrs	US$19.00m	0.062% R$ 292.9m
Donald Knauss	Independent Chairman of the Board	10.1yrs	US$555.22k	0.0016% R$ 7.7m
Maria Martinez	Independent Director	5.1yrs	US$335.08k	0.00027% R$ 1.3m
Dominic Caruso	Independent Director	6.2yrs	US$336.21k	0.00027% R$ 1.3m
Deborah Dunsire	Director	less than a year	geen gegevens	geen gegevens
James Hinton	Independent Director	2.8yrs	US$315.08k	geen gegevens
Webster Dunbar	Independent Director	2.6yrs	US$315.08k	geen gegevens
Kathleen Wilson-Thompson	Independent Director	2.8yrs	US$315.08k	geen gegevens
Richard Carmona	Independent Director	3.2yrs	US$313.71k	geen gegevens
Kevin Ozan	Independent Director	less than a year	US$139.34k	0.000010% R$ 47.2k
Bradley Lerman	Independent Director	6.6yrs	US$328.71k	geen gegevens

3.2yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van M1CK34 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

McKesson Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

McKesson Corporation, Annual General Meeting, Jul 31, 2024

Mckesson Corporation Elects Deborah Dunsire as New Director

Mckesson Corporation Elects Kevin Ozan as New Director

McKesson Appoints Crystal Lennartz to Health Mart and Health Mart Atlas

McKesson Corporation Announces Management Changes

McKesson Corporation, Annual General Meeting, Jul 21, 2023

Recent updates

McKesson, Oracle, Thoma Bravo Reportedly Among Finalists to Acquire Veradigm

McKesson Corporation Declares Quarterly Dividend, Payable on January 2, 2025

McKesson Launches InspiroGene, a Dedicated Business to Guide and Support the Commercialization of Cell and Gene Therapies

McKesson Corporation to Report Q2, 2025 Results on Nov 06, 2024

McKesson Corporation Declares Regular Dividend on Common Stock, Payable on October 1, 2024

McKesson Corporation to Report Q1, 2025 Results on Aug 07, 2024

McKesson Corporation, Annual General Meeting, Jul 31, 2024

Mckesson Corporation Elects Deborah Dunsire as New Director

McKesson Corporation Declares Quarterly Dividend, Payable on June 3, 2024

McKesson Corporation to Report Q4, 2024 Results on May 07, 2024

Mckesson Corporation Declares Quarterly Dividend, Payable on April 1, 2024

McKesson Corporation Reportedly Seeks Buyers for Canada's Rexall Pharmacy

McKesson Corporation (NYSE:MCK) acquired Compile, Inc.

Mckesson Corporation Elects Kevin Ozan as New Director

McKesson Corporation to Report Q3, 2024 Results on Feb 07, 2024

McKesson Appoints Crystal Lennartz to Health Mart and Health Mart Atlas

McKesson Corporation Announces Management Changes

McKesson Corporation Declares Quarterly Dividend, Payable on January 2, 2024

McKesson Corporation to Report Q2, 2024 Results on Nov 01, 2023

McKesson Corporation Raises Quarterly Dividend, Payable on October 2, 2023

McKesson Corporation to Report Q1, 2024 Results on Aug 02, 2023

McKesson Unveils New Private Brand of Over-the-Counter Pharmacy Products

McKesson Corporation, Annual General Meeting, Jul 21, 2023

McKesson Corporation, Annual General Meeting, Jul 21, 2023

McKesson Corporation Declares Regular Dividend on Common Stock, Payable on April 3, 2023

McKesson Corporation to Report Q3, 2023 Results on Feb 01, 2023

McKesson Corporation Declares Quarterly Dividend, Payable on January 3, 2023

McKesson Corporation to Report Q2, 2023 Results on Nov 01, 2022

McKesson Corporation (NYSE:MCK) signed a definitive agreement to acquire Rx Savings, LLC for approximately $880 million.

McKesson Corporation (NYSE:MCK) signed a definitive agreement to acquire Rx Savings, LLC for approximately $880 million.

McKesson Corporation Appoints Leann B. Smith as Next Chief Human Resources Officer

McKesson Corporation Raises Quarterly Dividend, Payable on October 3, 2022

McKesson Corporation to Report Q1, 2023 Results on Aug 03, 2022

McKesson Corporation, Annual General Meeting, Jul 22, 2022

McKesson Corporation to Report Q4, 2022 Results on May 05, 2022

McKesson Corporation Elects W. Roy Dunbar as New Director

AmerisourceBergen, Cardinal Health and McKesson Approve Opioid Settlement Agreement

McKesson Corporation Announces Executive Changes

McKesson Corporation Announces Board Changes, Effective April 1, 2022

McKesson Corporation Declares Regular Dividend, Payable on April 1, 2022

Quadrifolia Management GmbH agreed to acquire Austrian Business of McKesson Corporation from McKesson Corporation.

AmerisourceBergen, Cardinal Health and McKesson Announce Settlement with Cherokee Nation

McKesson Corporation Launches Rapid Returns Solution for Health Systems

John Chevedden Submits Shareholder Proposal to McKesson Corporation

McKesson Corporation Provides Earnings Guidance for the Fiscal Year 2022

McKesson Corporation Declares Quarterly Dividend, Payable on July 1, 2021

McKesson Announces the Launch of ScriptPAS

McKesson Begins Distributing the Johnson & Johnson COVID-19 Vaccine

McKesson Reportedly in Talks to Sell LloydsPharmacy Chain

McKesson to Advance Precision Medicine Options for Non-Small Cell Lung Cancer Patients

GeniusRx Announces Partnership with Mckesson

McKesson Corporation to Report Q3, 2021 Results on Feb 02, 2021

McKesson Corporation Fills Initial Government Orders for Moderna’s Covid-19 Vaccine

Amgen and McKesson Launch Strategic Agreement to Advance Cancer Innovation in Communities

McKesson Launches Ontada, an Oncology Technology and Insights Business Dedicated to Help Advance Cancer Research and Care

McKesson Appoints Dr. Kelvin A. Baggett to Chief Impact Officer, Effective from November 30, 2020

Walgreens Boots Alliance and McKesson Corporation the Formation of German Wholesale Joint Venture

McKesson Corporation's Board of Directors Elects Linda Mantia as New Independent Director

McKesson Corporation to Report Q2, 2021 Results on Nov 03, 2020

McKesson Corporation to Report Q1, 2021 Results on Aug 03, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur